Cardiovascular Systems Inc (CSII)

32.39
0.34 1.10
NASDAQ : Health Care
Prev Close 32.05
Open 31.97
Day Low/High 31.83 / 32.55
52 Wk Low/High 7.50 / 31.01
Volume 106.49K
Avg Volume 334.10K
Exchange NASDAQ
Shares Outstanding 32.71M
Market Cap 1.07B
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ATRO, BLL, CCE, CSII, EGN, EMR, HCI, IMPV, K, MANT, MLCO, MX, OI, RDS.A, RDS.B, TPRE, USCR, WMC Downgrades: CCO, CLF, GCAP, INCY, KMPR, OMCL, OMI, SHEN, SWIR, UEPS Initiations: ORMP Read on to get TheStreet Quant Ratings' detailed report:

FDA Approves Cardiovascular Systems' Replacement Saline Infusion Pump

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) today announced that the U.

Cardiovascular Systems, Inc. Reports Fiscal 2017 Third-Quarter Financial Results

Cardiovascular Systems, Inc. (NASDAQ: CSII): Conference Call Scheduled for Today, May 3, 2017, at 3:45 PM CT (4:45 PM ET) Revenues of $52.

Cardiovascular Systems Reaches Analyst Target Price

In recent trading, shares of Cardiovascular Systems, Inc have crossed above the average analyst 12-month target price of $30.50, changing hands for $30.69/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Thousands In Phoenix May Be Affected By Peripheral Artery Disease (PAD)

PAD is the biggest disease that most people have never heard about.

Thousands In Philadelphia May Be Affected By Peripheral Artery Disease (PAD)

PAD is the biggest disease that most people have never heard about.

Thousands In Dallas May Be Affected By Peripheral Artery Disease (PAD)

PAD is the biggest disease that most people have never heard about.

Thousands In Nashville May Be Affected By Peripheral Artery Disease (PAD)

PAD is the biggest disease that most people have never heard about.

Cardiovascular Systems Voluntarily Recalls 900 Pumps

Cardiovascular Systems Voluntarily Recalls 900 Pumps

Cardiovascular Systems' saline infusion pump is being recalled.

Cardiovascular Systems Initiates Voluntary Recall Of Saline Infusion Pump

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) today announced it has initiated a voluntary recall of its 7-10014 Saline Infusion Pump.

Cardiovascular Systems To Webcast Fiscal 2017 Third-Quarter Earnings Conference Call Wednesday, May 3

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) will host a live webcast of its fiscal 2017 third-quarter conference call on Wednesday, May 3, 2017, at 3:45 p.

Cardiovascular Systems, Inc. Receives Approval For The Diamondback 360® Coronary Orbital Atherectomy System (OAS) Micro Crown In Japan

Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII) announced that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the Diamondback 360 Coronary OAS Micro Crown as a frontline treatment for de novo severely...

Cardiovascular Systems, Inc. Receives Approval For The Diamondback 360® Coronary Orbital Atherectomy System (OAS) Micro Crown In The United States

Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII) announced that the United States Food and Drug Administration (FDA) has approved the Diamondback 360 ® Coronary OAS Micro Crown system to facilitate stent delivery in...

Cardiovascular Systems Enrolls First Subject In ECLIPSE Coronary Clinical Trial

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), in partnership with Cardiovascular Research Foundation (CRF), announces the first subject enrolled in its ECLIPSE clinical trial.

Commit To Buy Cardiovascular Systems At $22.50, Earn 13.2% Annualized Using Options

Investors eyeing a purchase of Cardiovascular Systems, Inc shares, but cautious about paying the going market price of $26.64/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $22.50 strike, which has a bid at the time of this writing of $1.55.

Cardiovascular Systems Announces Healthcare Veteran Martha Goldberg Aronson Joins Board Of Directors

Cardiovascular Systems (CSI) (NASDAQ: CSII) today announced the addition of independent board member Martha Goldberg Aronson, an experienced business executive with deep healthcare and medical industry experience.

Cardiovascular Systems Releases 1-Year Results From COAST IDE Study In Late-Breaking Presentation At 2017 Cardiovascular Research Technologies Conference

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), today released 1-year results from its Coronary Orbital Atherectomy System Study (COAST) in a late-breaking presentation at the 2017 Cardiovascular Research Technologies...

Cardiovascular Systems To Present At LEERINK Partners 6th Annual Global Healthcare Conference

On Thursday, February 16, 2017, Cardiovascular Systems' (NASDAQ: CSII) Chairman, President and Chief Executive Officer, Scott Ward, and Chief Financial Officer, Larry Betterley, will present at the LEERINK Partners 6 th...

Landmark Study From Cardiovascular Systems Demonstrates Sustained Benefit Of Endovascular Intervention In Patients With Lower Extremity Peripheral Artery Disease

Cardiovascular Systems (CSI) (NASDAQ: CSII) presented six-month data from its LIBERTY 360° post-market study in a presentation at the 29th International Symposium on Endovascular Therapy (ISET) in Hollywood, Florida.

Cardiovascular Systems, Inc. Reports Fiscal 2017 Second-Quarter Financial Results

Cardiovascular Systems, Inc. Reports Fiscal 2017 Second-Quarter Financial Results

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, today reported financial...

Cardiovascular Systems To Webcast Fiscal 2017 Second-Quarter Earnings Conference Call Wednesday, January 25

Cardiovascular Systems To Webcast Fiscal 2017 Second-Quarter Earnings Conference Call Wednesday, January 25

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) will host a live webcast of its fiscal 2017 second-quarter conference call on Wednesday, January 25, 2017, at 3:45 p.

Commit To Purchase Cardiovascular Systems At $17.50, Earn 10.1% Annualized Using Options

Commit To Purchase Cardiovascular Systems At $17.50, Earn 10.1% Annualized Using Options

Investors eyeing a purchase of Cardiovascular Systems, Inc stock, but cautious about paying the going market price of $23.28/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June 2017 put at the $17.50 strike, which has a bid at the time of this writing of 95 cents.

Commit To Purchase Cardiovascular Systems At $17.50, Earn 10.1% Annualized Using Options

Commit To Purchase Cardiovascular Systems At $17.50, Earn 10.1% Annualized Using Options

Investors eyeing a purchase of Cardiovascular Systems, Inc stock, but cautious about paying the going market price of $23.28/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June 2017 put at the $17.50 strike, which has a bid at the time of this writing of 95 cents.

Cardiovascular Systems, Inc. Signs Distribution Agreement With Medikit Co., Ltd. For Japan

Cardiovascular Systems, Inc. Signs Distribution Agreement With Medikit Co., Ltd. For Japan

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) has signed an exclusive distribution agreement with Medikit Co.

Cardiovascular Systems, Inc. In Collaboration With Cardiovascular Research Foundation Debuts Largest Randomized Trial To Study Coronary Atherectomy For Calcified Coronary Lesions At Transcatheter Cardiovascular Therapeutics Conference

Cardiovascular Systems, Inc. In Collaboration With Cardiovascular Research Foundation Debuts Largest Randomized Trial To Study Coronary Atherectomy For Calcified Coronary Lesions At Transcatheter Cardiovascular Therapeutics Conference

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), today debuted the design of its new ECLIPSE clinical trial in a presentation at the Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.

Cardiovascular Systems Becomes Oversold (CSII)

Cardiovascular Systems Becomes Oversold (CSII)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Cardiovascular Systems, Inc. Reports Fiscal 2017 First-Quarter Financial Results

Cardiovascular Systems, Inc. Reports Fiscal 2017 First-Quarter Financial Results

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, today reported financial...

TheStreet Quant Rating: C- (Hold)